Alder looks to raise $115M-plus; Radius touts PhIII osteoporosis data;

@FierceBiotech: New special report: Best and worst 2014 biotech performers on Wall Street. Feature | Follow @FierceBiotech

@JohnCFierce: Astellas adds to deal spree with expanded $675M-plus Cytokinetics pact. Article | Follow @JohnCFierce

@DamianFierce: $ABBV's Viekira pitch includes this boomer-focused quiz thing on Facebook, featuring rotary phones and candy paper. More | Follow @DamianFierce

> Seattle-based Alder Biopharmaceuticals is out to raise more than $115 million in a secondary offering. Story

> Waltham, MA-based Radius Health says it garnered positive top-line data from its Phase III study of abaloparatide-SC for the reduction of fractures in postmenopausal osteoporosis. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Asante files for $45M IPO to market cheap, easy insulin pump. More | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ interview comments: NIH launches crowdsourcing challenge to commercialize its neurological medical devices. Report | Follow @VarunSaxena2

@EmilyWFierce: Check out @FierceBiotech's latest special report for this year's biotech winners and losers. More | Follow @EmilyWFierce

> Study: Devices for obstructive sleep apnea could improve symptoms of depression. Article

> Trio of med techs file IPOs to raise a total of up to almost $140M. Story

Pharma News

@FiercePharma: Pfizer turns the sex talk toward 50-ish women with menopause awareness push. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Cubist has its Zerbaxa OK. Can Merck make the launch justify its $9.5B buyout? Article | Follow @CarlyHFierce

> With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck's Keytruda. More

> Justice Department sues Omnicare for rigging kickbacks with Abbott. Report

> Want to place biopharma bets for 2015? JPM flags Alexion, BioMarin and Bristol-Myers. Article

> SEC says insider made $10M on Abbott, CFR deal. Story

Biotech Research News

> Northwestern team claims they have found the right way to ID Alzheimer's early on. Report

> New research points to a key driver--and new drug target--behind hepatitis infections. More

> Brown U dean points to a possible suspect driving metastasis. Article

> Stem cell investigator resigns in wake of controversy. Item

> J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration. Story

Pharma Manufacturing News

> Merck, NewLink nab $30M from BARDA to help manufacture Ebola vax. Item

> Bayer picks Cardinal Health to manufacture Xofigo in U.S. News

> Fujifilm becomes part of U.S. pandemic defense with deal for Kalon Biotherapeutics. More

> India warns Egyptian companies claiming to have Sovaldi for sale. Article

> Fresenius closes out recall started two years ago. Story

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.